Clearmind Medicine (CMND) announced the filing of a patent application in South Korea covering compositions containing its proprietary compound, 5-methoxy-2-aminoindane, for the treatment of depression. This filing further strengthens Clearmind’s global intellectual property portfolio for MEAI, a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without the psychoactive effects associated with traditional psychedelics.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces publication of U.S. patent application
- Psychedelic: Compass Pathways, NeuroKaire enter R&D collaboration
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial
- Clearmind appoints Mary-Elizabeth Gifford as chief of global impact
- Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial